Administration of NRF2 activator, which would be favorable for reinvigorating anti-tumor immunity and conferring the metabolic liabilities on cancer cells, in combination with inhibitors of glutamate and/or NEAA synthesis may be an effective anti-tumor therapy from the viewpoint of interaction between cancer cells and their microenvironment. This evidence concerns the gene NFE2L2 and neoplasm.